Inhibitors of mGluR5 have been extensively studied in the neurodevelopmental disorder fragile X syndrome (FXS) as well as other psychiatric disorders (Gravius et al., 2010; Michalon et al., 2012; Scharf et al., 2015; Berry-Kravis et al., 2017). This evidence concerns the gene GRM5 and fragile X syndrome.